Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Julie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, Erika Vacchelli & Guido Kroemer. (2020) Trial watch: STING agonists in cancer therapy. OncoImmunology 9:1.
Read now
Read now
Junqi Wu, Jinwei Dai, Yuyang Zhang, Jing Wang, Lei Huang, Hongmei Ding, Tiejun Li, Yuefan Zhang, Junqin Mao & Shichong Yu. (2019) Synthesis of Novel Xanthone Analogues and Their Growth Inhibitory Activity Against Human Lung Cancer A549 Cells. Drug Design, Development and Therapy 13, pages 4239-4246.
Read now
Read now
Michael R. Horsman. (2016) Realistic biological approaches for improving thermoradiotherapy. International Journal of Hyperthermia 32:1, pages 14-22.
Read now
Read now
Michael R. Horsman. (2015) Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation. International Journal of Hyperthermia 31:5, pages 453-459.
Read now
Read now
Ane B. Iversen, Morten Busk & Michael R. Horsman. (2013) Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. Acta Oncologica 52:7, pages 1320-1326.
Read now
Read now
Xiaorong Sun, Ligang Xing, C. Clifton Ling & Gloria C. Li. (2010) The effect of mild temperature hyperthermia on tumour hypoxia and blood perfusion: relevance for radiotherapy, vascular targeting and imaging. International Journal of Hyperthermia 26:3, pages 224-231.
Read now
Read now
Robert J. Griffin & Peter M. Corry. (2009) Commentary on classic paper in hyperthermic oncology ‘Tumour oxygenation is increased by hyperthermia at mild temperatures’ by CW Song et al., 1996. International Journal of Hyperthermia 25:2, pages 96-98.
Read now
Read now
Michael R. Horsman. (2008) Angiogenesis and vascular targeting: Relevance for hyperthermia. International Journal of Hyperthermia 24:1, pages 57-65.
Read now
Read now
Olav Dahl, Erling Dahl Borkamo & Øystein Fluge. (2008) Current status of antivascular therapy and targeted treatment in the clinic. International Journal of Hyperthermia 24:1, pages 97-110.
Read now
Read now
S. L. Hokland & M. R. Horsman. (2007) The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization. International Journal of Hyperthermia 23:7, pages 599-606.
Read now
Read now
Rachana Visaria, John C. Bischof, Melissa Loren, Brent Williams, Emad Ebbini, Giulio Paciotti & Robert Griffin. (2007) Nanotherapeutics for enhancing thermal therapy of cancer. International Journal of Hyperthermia 23:6, pages 501-511.
Read now
Read now
Articles from other publishers (12)
Xianghui Li, Haoran Wang, Yuanyuan Chen, Zhiyan Li, Song Liu, Wenxian Guan, Youkun Lin, Cunwei Cao, Wenjun Zheng & Jinhui Wu. (2023) Novel emerging nano-assisted anti-cancer strategies based on the STING pathway. Acta Materia Medica 2:3.
Crossref
Crossref
Nimi Vashi & Samuel F. Bakhoum. (2021) The Evolution of STING Signaling and Its Involvement in Cancer. Trends in Biochemical Sciences 46:6, pages 446-460.
Crossref
Crossref
Lucianna Rabelo Pessoa de Siqueira, Paulo André Teixeira de Moraes Gomes, Larissa Pelágia de Lima Ferreira, Moacyr Jesus Barreto de Melo Rêgo & Ana Cristina Lima Leite. (2019) Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues. European Journal of Medicinal Chemistry 170, pages 237-260.
Crossref
Crossref
Jie Liu, Fan Zhou, Lei Zhang, Huailing Wang, Jianrun Zhang, Cao Zhang, Zhenlei Jiang, Yanbing Li, Zhijun Liu & Heru Chen. (2018) DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions. European Journal of Medicinal Chemistry 143, pages 1768-1778.
Crossref
Crossref
Jie Liu, Jianrun Zhang, Huailing Wang, Zhijun Liu, Cao Zhang, Zhenlei Jiang & Heru Chen. (2017) Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them. European Journal of Medicinal Chemistry 133, pages 50-61.
Crossref
Crossref
Robert J. Griffin, Brent W. Williams, Nathan A. Koonce, John C. Bischof, Chang W. Song, Rajalakshmi Asur & Meenakshi Upreti. (2012) Vascular Disrupting Agent Arsenic Trioxide Enhances Thermoradiotherapy of Solid Tumors. Journal of Oncology 2012, pages 1-7.
Crossref
Crossref
Michael R. Horsman, Jens Overgaard & Dietmar W. Siemann. 2010. Tumor Microenvironment. Tumor Microenvironment
353
376
.
Henry C. Mandeville & Peter J. Hoskin. 2010. Vascular Disruptive Agents for the Treatment of Cancer. Vascular Disruptive Agents for the Treatment of Cancer
231
250
.
Michael R. Horsman & Dietmar W. Siemann. 2009. Cancer Microenvironment and Therapeutic Implications. Cancer Microenvironment and Therapeutic Implications
137
156
.
John W. LippertIIIIII. (2007) Vascular disrupting agents. Bioorganic & Medicinal Chemistry 15:2, pages 605-615.
Crossref
Crossref
Michael R. Horsman & Dietmar W. Siemann. (2006) Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies. Cancer Research 66:24, pages 11520-11539.
Crossref
Crossref
Michael R. Horsman. (2006) In response to Drs. van der Zee and van Rhoon. International Journal of Radiation Oncology*Biology*Physics 66:2, pages 634.
Crossref
Crossref